Table 4 Descriptive statistics of medication were taken during the study period among chronic heart failure patients, in Ethiopia from December 2023 to April 2024 (n = 360).
Items | Types of class of medications | Route of administrations | Cost tiers | |
|---|---|---|---|---|
Intravenous % | Per-oral % | |||
Furosemide | Loop diuretics | 6 (1.67%) | 354 (98.33) | Tier 1 |
Enalapril | ACEI | 256 (71.11%) | Tier 1 | |
Spironolactone | MRA | 249 (69.17%) | Tier 1 | |
Metoprolol succinate | BB | 193 (53.61%) | Tier 1 | |
Metoprolol tartrate | BB | 49 (13.61%) | Tier 1 | |
Warfarin | Vit k antagonist | 63 (17.50%) | Tier 1 | |
Dapagliflozin | SGLTI | 59 (16.39% %) | Tier 3 | |
NPH insulin | Intermediate-acting insulin | 25 (6.94%) | Tier2 | |
UFH | Heparin | 24 (6.67%) | Tier 2 | |
Lisinopril | ACEI | 8 (2.22%) | Tier 1 | |
Valsartan | ARB | 11 (3.06%) | Tier 1 | |
Losartan | ARB | 15 (4.17%) | Tier 1 | |
Aspirin | Antiplatelet | 118 (32.78%) | Tier 1 | |
Atorvastatin | Lipid-lowering agent | 130 (36.11%) | Tier 1 | |
Clopidogrel | Antiplatelet | 33 (9.22%) | Tier 1 | |
Amlodipine | Calcium channel blockers | 62 (17.22%) | Tier 1 | |
Ceftriaxone | Cephalosporin | 49 (13.61%) | Tier 2 | |
Doxycycline | Tetracycline | 39 (10.83%) | Tier 1 | |
Crystal penicillin | Penicillin | 29 (8.06%) | Tier 1 | |
Gentamycin | Aminoglycoside | 18 (5%) | Tier 1 | |
Vancomycin | Glycopeptide | 14 (3.89%) | Tier 2 | |
Ferrous sulfate | 56 (15.56%) | Tier 1 | ||
Dopamine | Vasodilator | 12 (3.33%) | Tier 2 | |
Digoxin | Digitals glycoside | 25 (6.94%) | Tier 2 | |
